- Conditions
- Crohn's Disease
- Interventions
- Certolizumab Pegol (CDP870)
- Biological
- Lead sponsor
- UCB Pharma SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2012
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Little Rock, Arkansas + 37 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- CNTO 148 (Golimumab), Placebo, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 18 Years
- Enrollment
- 173 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Los Angeles, California • San Francisco, California • Augusta, Georgia + 4 more
- Conditions
- Crohn Disease
- Interventions
- UVADEX and UVAR XTS Photopheresis System
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Arthritis, Juvenile Idiopathic
- Interventions
- Double-Blind Adalimumab/Placebo + MTX, Double-Blind Adalimumab/Placebo, OLE BSA Adalimumab +/- MTX, OLE FD Adalimumab +/- MTX
- Biological · Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 4 Years to 17 Years
- Enrollment
- 171 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2010
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- Withdrawal of anti-TNF therapy
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 4 Years to 20 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 13 more